Virginia G Kaklamani

Summary

Affiliation: Northwestern University
Country: USA

Publications

  1. ncbi request reprint Role of capecitabine (Xeloda) in breast cancer
    Virginia G Kaklamani
    Department of Medicine, Feinberg School of Medicine, Northwestern University, Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
    Expert Rev Anticancer Ther 3:137-44. 2003
  2. ncbi request reprint TGFBR1*6A and cancer risk: a meta-analysis of seven case-control studies
    Virginia G Kaklamani
    Cancer Genetics Program, Division of Hematology Oncology, Evanston Northwestern Healthcare, Chicago, IL, USA
    J Clin Oncol 21:3236-43. 2003
  3. ncbi request reprint Gene expression in breast cancer
    Virginia G Kaklamani
    Department of Medicine, Division of Hematology Oncology, Feinberg School of Medicine of Northwestern University, 676 North St Clair Street, Suite 850, Chicago, IL 60611, USA
    Curr Treat Options Oncol 7:123-8. 2006
  4. pmc Variants of the adiponectin and adiponectin receptor 1 genes and breast cancer risk
    Virginia G Kaklamani
    Division of Hematology Oncology, Department of Medicine, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Cancer Res 68:3178-84. 2008
  5. pmc Adiponectin pathway polymorphisms and risk of breast cancer in African Americans and Hispanics in the Women's Health Initiative
    Virginia G Kaklamani
    Division Hematology Oncology, Department of Medicine, Northwestern University, 676 North St Clair Street, Suite 850, Chicago, IL, 60611, USA
    Breast Cancer Res Treat 139:461-8. 2013
  6. pmc Targeting angiogenesis in metastatic breast cancer
    Sangeetha Reddy
    Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
    Oncologist 17:1014-26. 2012
  7. doi request reprint Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib
    Virginia G Kaklamani
    Division of Hematology Oncology, Northwestern University, 676 North St Clair Street, Suite 850, Chicago, IL 60611, USA
    Breast Cancer Res Treat 132:833-42. 2012
  8. pmc The role of the fat mass and obesity associated gene (FTO) in breast cancer risk
    Virginia Kaklamani
    Cancer Genetics Program, Division of Hematology Oncology, Department of Medicine and Robert H, Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, 676 N St Clair st suite 850, Chicago, IL 60611, USA
    BMC Med Genet 12:52. 2011
  9. doi request reprint Global experience with ixabepilone in breast cancer
    Virginia G Kaklamani
    Cancer Genetics Program, Division of Hematology Oncology, Northwestern University, 676 N St Clair St, Suite 850, Chicago, IL 60611, USA
    Expert Rev Anticancer Ther 11:683-92. 2011
  10. ncbi request reprint Role of TGF-beta in cancer and the potential for therapy and prevention
    Virginia G Kaklamani
    Northwestern University Feinberg School of Medicine, Division of Hematology Oncology, Department of Medicine, Robert H Lurie Comprehensive Cancer Center, 676 N St Clair Street, Suite 880, Chicago, IL 60611, USA
    Expert Rev Anticancer Ther 4:649-61. 2004

Collaborators

Detail Information

Publications31

  1. ncbi request reprint Role of capecitabine (Xeloda) in breast cancer
    Virginia G Kaklamani
    Department of Medicine, Feinberg School of Medicine, Northwestern University, Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
    Expert Rev Anticancer Ther 3:137-44. 2003
    ..This review will place the available data on the use of capecitabine in metastatic breast cancer as a single agent or as part of a combination regime in context...
  2. ncbi request reprint TGFBR1*6A and cancer risk: a meta-analysis of seven case-control studies
    Virginia G Kaklamani
    Cancer Genetics Program, Division of Hematology Oncology, Evanston Northwestern Healthcare, Chicago, IL, USA
    J Clin Oncol 21:3236-43. 2003
    ..This study was undertaken to analyze all published case-control studies on TGFBR1*6A and cancer and determine whether TGFBR1*6A is associated with cancer...
  3. ncbi request reprint Gene expression in breast cancer
    Virginia G Kaklamani
    Department of Medicine, Division of Hematology Oncology, Feinberg School of Medicine of Northwestern University, 676 North St Clair Street, Suite 850, Chicago, IL 60611, USA
    Curr Treat Options Oncol 7:123-8. 2006
    ..Tailoring our treatment based on individual tumor characteristics will help us develop better therapeutic strategies and save many patients from receiving unnecessary toxic therapy...
  4. pmc Variants of the adiponectin and adiponectin receptor 1 genes and breast cancer risk
    Virginia G Kaklamani
    Division of Hematology Oncology, Department of Medicine, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Cancer Res 68:3178-84. 2008
    ..89; P(trend) = 0.001). This is the first report of an association between functionally relevant variants of the adiponectin pathway and breast cancer risk. The results warrant further studies of the adiponectin pathway in breast cancer...
  5. pmc Adiponectin pathway polymorphisms and risk of breast cancer in African Americans and Hispanics in the Women's Health Initiative
    Virginia G Kaklamani
    Division Hematology Oncology, Department of Medicine, Northwestern University, 676 North St Clair Street, Suite 850, Chicago, IL, 60611, USA
    Breast Cancer Res Treat 139:461-8. 2013
    ..As the rates of obesity and diabetes increase in African Americans and Hispanics, adiponectin and its functional SNPs may aid in breast cancer risk assessment...
  6. pmc Targeting angiogenesis in metastatic breast cancer
    Sangeetha Reddy
    Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
    Oncologist 17:1014-26. 2012
    ..Sequential use of antiangiogenic agents with differing mechanisms of action may be an effective approach. Despite setbacks, angiogenesis will likely remain an important target of treatment for selected patients with MBC...
  7. doi request reprint Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib
    Virginia G Kaklamani
    Division of Hematology Oncology, Northwestern University, 676 North St Clair Street, Suite 850, Chicago, IL 60611, USA
    Breast Cancer Res Treat 132:833-42. 2012
    ..This combination offers an alternative non-anthracycline-containing regimen for women with HER2 positive breast cancer...
  8. pmc The role of the fat mass and obesity associated gene (FTO) in breast cancer risk
    Virginia Kaklamani
    Cancer Genetics Program, Division of Hematology Oncology, Department of Medicine and Robert H, Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, 676 N St Clair st suite 850, Chicago, IL 60611, USA
    BMC Med Genet 12:52. 2011
    ..Our objective was to evaluate tissue expression of FTO in breast and the role of FTO SNPs in predicting breast cancer risk...
  9. doi request reprint Global experience with ixabepilone in breast cancer
    Virginia G Kaklamani
    Cancer Genetics Program, Division of Hematology Oncology, Northwestern University, 676 N St Clair St, Suite 850, Chicago, IL 60611, USA
    Expert Rev Anticancer Ther 11:683-92. 2011
    ..Further information on the global patterns of use of ixabepilone will assist in optimizing the use of this novel therapy...
  10. ncbi request reprint Role of TGF-beta in cancer and the potential for therapy and prevention
    Virginia G Kaklamani
    Northwestern University Feinberg School of Medicine, Division of Hematology Oncology, Department of Medicine, Robert H Lurie Comprehensive Cancer Center, 676 N St Clair Street, Suite 880, Chicago, IL 60611, USA
    Expert Rev Anticancer Ther 4:649-61. 2004
    ..In addition, it is predicted that inhibitors of the TGF-beta signaling pathway will find their way into cancer clinical trials, leading to delays in tumor progression and improvements in overall survival...
  11. ncbi request reprint A genetic signature can predict prognosis and response to therapy in breast cancer: Oncotype DX
    Virginia Kaklamani
    Department of Medicine, Division of Hematology Oncology, Feinberg School of Medicine of Northwestern University 676 North St Clair Street, Suite 850, Chicago, IL, USA
    Expert Rev Mol Diagn 6:803-9. 2006
    ..Tailoring our treatment based on individual tumor characteristics will help us develop better therapeutic strategies and save many of our patients from receiving unnecessary toxic therapy...
  12. ncbi request reprint Combined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast cancer risk
    Virginia G Kaklamani
    Cancer Genetics Program, Division of Hematology Oncology, Department of Medicine, Feinberg School of Medicine and Robert H Lurie Comprehensive Cancer Center, Northwestern University, 676 North St Clair Street, Chicago, IL 60611, USA
    Cancer Res 65:3454-61. 2005
    ..25-3.87). This is the first study assessing the TGF-beta signaling pathway through two common and functionally relevant TGFBR1 and TGFB1 variants. This approach may predict breast cancer risk in a large subset of the population...
  13. pmc Variants of the adiponectin (ADIPOQ) and adiponectin receptor 1 (ADIPOR1) genes and colorectal cancer risk
    Virginia G Kaklamani
    Cancer Genetics Program, Division of Hematology and Oncology, Department of Medicine and Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
    JAMA 300:1523-31. 2008
    ..While there is evidence of an association between circulating adiponectin levels and colorectal cancer risk, no association between genes of the adiponectin pathway and colorectal cancer have been reported to date...
  14. pmc Role of polymorphisms in Adamantiades-Beh├žet's disease
    Virginia G Kaklamani
    Cancer Genetics Program, Division of Hematology Oncology, Department of Medicine, and Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
    J Rheumatol 35:2376-8. 2008
    ..We tested whether incidence of these polymorphisms would differ in patients with A-BD compared with healthy controls of similar age and geographic location...
  15. ncbi request reprint Adjuvant therapy of breast cancer
    Virginia G Kaklamani
    Department of Medicine, Division of Hematology Oncology, Feinberg School of Medicine of Northwestern University, Chicago, Illinois 60611, USA
    Cancer Invest 23:548-60. 2005
    ....
  16. ncbi request reprint TGFBR1*6A may contribute to hereditary colorectal cancer
    Yansong Bian
    Cancer Genetics Program, Division of Hematology Oncology, Department of Medicine, Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, 676 N St Clair St, Suite 880, Chicago, IL 60611, USA
    J Clin Oncol 23:3074-8. 2005
    ..To test this hypothesis, we determined whether TGFBR16A contributes to a proportion of mismatch repair (MMR) gene mutation-negative hereditary nonpolyposis colorectal cancer (HNPCC) patients...
  17. ncbi request reprint The assessment and management of cancer treatment-related diarrhea
    Bridget E O'Brien
    Northwestern Medical Faculty Foundation, Northwestern University, Chicago, IL 60611, USA
    Clin Colorectal Cancer 4:375-81; discussion 382-3. 2005
    ..Early recognition and management of diarrhea will be essential to improve control of diarrhea, and in turn will positively impact patients' quality of life...
  18. ncbi request reprint HER2-positive breast cancer: current and future treatment strategies
    Ryan H Engel
    Division of Hematology Oncology, Northwestern University Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
    Drugs 67:1329-41. 2007
    ..Whereas pertuzumab, a humanised monoclonal antibody, directed against heterodimerisation of HER2 and HER3 has entered phase II and III clinical trials...
  19. ncbi request reprint Somatic acquisition and signaling of TGFBR1*6A in cancer
    Boris Pasche
    Cancer Genetics Program, Division of Hematology Oncology, Department of Medicine, The Feinberg School of Medicine, Northwestern, University, Chicago, Ill 60611, USA
    JAMA 294:1634-46. 2005
    ..Epidemiological studies suggest that TGFBR1*6A may act as a tumor susceptibility allele. How TGFBR1*6A contributes to cancer development is largely unknown...
  20. pmc No major association between TGFBR1*6A and prostate cancer
    Virginia Kaklamani
    Cancer Genetics Program, Division of Hematology Oncology, Department of Medicine, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
    BMC Genet 5:28. 2004
    ..080) but the differences in TGFBR1*6A genotype distribution between cases and controls did not reach statistical significance (p = 0.67). Our data suggest that TGFBR1*6A does not contribute to the development of prostate cancer...
  21. pmc Somatic acquisition of TGFBR1*6A by epithelial and stromal cells during head and neck and colon cancer development
    Yansong Bian
    Cancer Genetics Program, Division of Hematology Oncology, Department of Medicine, Northwestern University, Chicago, IL 60611, USA
    Hum Mol Genet 16:3128-35. 2007
    ..They also represent the first human report of somatically acquired altered stromal TGF-beta signaling during oncogenesis and the first report of a concordant mutation in the stromal and epithelial compartments in colon cancer...
  22. pmc Constitutively decreased TGFBR1 allelic expression is a common finding in colorectal cancer and is associated with three TGFBR1 SNPs
    Boris Pasche
    Division of Hematology Oncology, The University of Alabama at Birmingham and UAB Comprehensive Cancer Center, Birmingham, AL 35203, USA
    J Exp Clin Cancer Res 29:57. 2010
    ..This phenotype was first observed in mice, then in lymphoblastoid cell lines from patients with microsatellite stable colorectal tumors...
  23. ncbi request reprint Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer?
    Virginia G Kaklamani
    Department of Medicine, Division of Hematology Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Clin Breast Cancer 4:S26-33. 2003
    ..In this article, we are attempting to provide an overview of current use of doxorubicin and epirubicin in breast cancer..
  24. pmc New insights into breast cancer genetics and impact on patient management
    Diana S Rosman
    Cancer Genetics Program, Division of Hematology Oncology, Department of Medicine and Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Curr Treat Options Oncol 8:61-73. 2007
    ..In the next decade, screening for combinations of high and low penetrance genes will likely permit the identification of a large fraction of inherited breast cancer cases and will further reduce the burden of familial breast cancer...
  25. ncbi request reprint Role of efaproxiral in metastatic brain tumors
    Ryan H Engel
    Department of Medicine, Division of Hematology Oncology, Feinberg School of Medicine, Northwestern University, Robert H Lurie Comprehensive Cancer Center, 676 North Street Clair Street, Suite 850, Chicago, IL 60622, USA
    Expert Rev Anticancer Ther 6:477-85. 2006
    ..Furthermore, the combination of efaproxiral with radiotherapy is being investigated in other solid tumors...
  26. pmc Reevaluating cathepsin D as a biomarker for breast cancer: serum activity levels versus histopathology
    Daniel E Abbott
    Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
    Cancer Biol Ther 9:23-30. 2010
    ....
  27. ncbi request reprint Transforming Growth Factor Beta and breast cancer
    Virginia Kaklamani
    Division of Hematology Oncology, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
    Cancer Treat Res 126:129-56. 2005
  28. ncbi request reprint 90Y radioembolization of metastatic breast cancer to the liver: toxicity, imaging response, survival
    Affaan K Bangash
    Department of Radiology, Northwestern University Feinberg School of Medicine, 676 N St Clair, Suite 800, Chicago, IL 60611, USA
    J Vasc Interv Radiol 18:621-8. 2007
    ..To present data from patients with breast cancer liver metastases who underwent radioembolization with yttrium (90Y) microspheres...
  29. ncbi request reprint New targeted therapies in breast cancer
    Virginia Kaklamani
    Division of Hematology Oncology, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
    Semin Oncol 31:20-5. 2004
    ..In the next few years, and as trials with the above agents mature, we will further define the role of these targeted agents in the treatment of breast cancer...
  30. ncbi request reprint TGF-beta signaling alterations in cancer
    Yansong Bian
    Division of Hematology Oncology, Department of Medicine, Northwestern University Medical School, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA
    Cancer Treat Res 115:73-94. 2003
  31. ncbi request reprint Adjuvant therapy of breast cancer in the elderly: does one size fit all?
    William J Gradishar
    JAMA 293:1118-20. 2005